216 related articles for article (PubMed ID: 23686435)
1. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone.
Winans SA; Luce AM; Hasbun R
Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
[TBL] [Abstract][Full Text] [Related]
3. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
[TBL] [Abstract][Full Text] [Related]
4. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore.
Chan M; Ooi CK; Wong J; Zhong L; Lye D
BMC Infect Dis; 2017 Jul; 17(1):474. PubMed ID: 28683717
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
[No Abstract] [Full Text] [Related]
6. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
Lefèvre B; Hoen B; Goehringer F; Sime WN; Aissa N; Alauzet C; Jeanmaire E; Hénard S; Filippetti L; Selton-Suty C; Agrinier N;
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2605-2616. PubMed ID: 34383175
[TBL] [Abstract][Full Text] [Related]
7. Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia.
Mohamed A; Bennett N; Ploetz J; Aragon L; Kennedy K; Boyd S
Int J Antimicrob Agents; 2022 Sep; 60(3):106632. PubMed ID: 35787919
[TBL] [Abstract][Full Text] [Related]
8. Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.
Lee B; Tam I; Weigel B; Breeze JL; Paulus JK; Nelson J; Allison GM
J Antimicrob Chemother; 2015 Aug; 70(8):2389-96. PubMed ID: 26024869
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections.
Patel UC; McKissic EL; Kasper D; Lentino JR; Pachucki CT; Lee T; Lopansri BK
Int J Clin Pharm; 2014 Dec; 36(6):1282-9. PubMed ID: 25186790
[TBL] [Abstract][Full Text] [Related]
10. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.
Wieland BW; Marcantoni JR; Bommarito KM; Warren DK; Marschall J
Clin Infect Dis; 2012 Mar; 54(5):585-90. PubMed ID: 22144536
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible
Hamad Y; Connor L; Bailey TC; George IA
Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944
[TBL] [Abstract][Full Text] [Related]
13. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
Li J; Echevarria KL; Traugott KA
Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
Youngster I; Shenoy ES; Hooper DC; Nelson SB
Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
16. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus.
Gern BH; Greninger AL; Weissman SJ; Stapp JR; Tao Y; Qin X
Ann Clin Microbiol Antimicrob; 2018 Feb; 17(1):5. PubMed ID: 29463249
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus.
Wynn M; Dalovisio JR; Tice AD; Jiang X
South Med J; 2005 Jun; 98(6):590-5. PubMed ID: 16004164
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible
Carr DR; Stiefel U; Bonomo RA; Burant CJ; Sims SV
Open Forum Infect Dis; 2018 May; 5(5):ofy089. PubMed ID: 30568987
[TBL] [Abstract][Full Text] [Related]
19. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D
Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
[TBL] [Abstract][Full Text] [Related]
20. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
